AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 33484158 — intervention group
Group type: COMPARATOR
Intervention: Standard 'hands-off' care (Control)
Number of subjects: 156
Study 34986394 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower dose rNAPc2
Number of subjects: 160
Study 34986394 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dose rNAPc2
Number of subjects: 160
Study 34986394 — intervention group
Group type: COMPARATOR
Intervention: Heparin (control)
Number of subjects: 160
Study 34986394 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (rNAPc2 and Heparin)
Number of subjects: 160
Study 33556039 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved latrine use
Number of subjects: 32172
Study 33556039 — intervention group
Group type: COMPARATOR
Intervention: Unimproved latrine use
Number of subjects: 32172
Study 33556039 — intervention group
Group type: COMPARATOR
Intervention: Open defecation
Number of subjects: 32172
Study 32798588 — intervention group
Group type: COMPARATOR
Intervention: Rinsing (without toothbrushing)
Number of subjects: 15
Study 32798588 — intervention group
Group type: COMPARATOR
Intervention: Control (toothbrushing without toothpaste)
Number of subjects: 15
Study 32798588 — intervention group
Group type: COMPARATOR
Intervention: Brushing (toothbrushing with toothpaste)
Number of subjects: 15
Study 32798588 — intervention group
Group type: COMPARATOR
Intervention: Brushing + Rinsing
Number of subjects: 15
Study 32798588 — intervention group
Group type: COMPARATOR
Intervention: Rinsing + Brushing
Number of subjects: 15
Study 32000549 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF) applied to the wound and covered with Vaseline gauze and wet dressing
Number of subjects: 0
Study 32000549 — intervention group
Group type: COMPARATOR
Intervention: Control (Vaseline petrolatum gauze) applied to the wound
Number of subjects: 0
Study 32000549 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Fibrin (PRF)
Number of subjects: 0
Study 32000549 — intervention group
Group type: COMPARATOR
Intervention: Control (Vaseline petrolatum gauze)
Number of subjects: 0
Study 33694074 — intervention group
Group type: EXPERIMENTAL
Intervention: Encapsulated pupae
Number of subjects: 5
Study 33694074 — intervention group
Group type: EXPERIMENTAL
Intervention: Unprotected pupae
Number of subjects: 5
Study 33694074 — intervention group
Group type: COMPARATOR
Intervention: Pupae released between soybean lines (V2 and V9)
Number of subjects: 5
Study 33694074 — intervention group
Group type: EXPERIMENTAL
Intervention: Pupae released in reproductive stages (R1, R4, R7)
Number of subjects: 5
Study 33152978 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight
Number of subjects: 100
Study 33152978 — intervention group
Group type: EXPERIMENTAL
Intervention: Thyromental Distance (TMD)
Number of subjects: 100
Study 33152978 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternomental Distance (SMD)
Number of subjects: 100
Study 33152978 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Plane to Chin Distance by Weight ratio (FPCD/Wt ratio)
Number of subjects: 100
Study 33152978 — intervention group
Group type: EXPERIMENTAL
Intervention: FPCD/Wt ratio
Number of subjects: 100
Study 35959348 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided PICC combined with predictive nursing
Number of subjects: 88
Study 33601732 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based Cognitive Behavioral Therapy (CCBT) with therapeutic support
Number of subjects: 50
Study 33601732 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 50
Study 33601732 — intervention group
Group type: EXPERIMENTAL
Intervention: High homework compliance in CCBT group
Number of subjects: 50
Study 33601732 — intervention group
Group type: EXPERIMENTAL
Intervention: Low homework compliance in CCBT group
Number of subjects: 50
Study 35045969 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical fixation with K‐wires
Number of subjects: 500
Study 35045969 — intervention group
Group type: COMPARATOR
Intervention: Moulded cast
Number of subjects: 500
Study 33019861 — intervention group
Group type: EXPERIMENTAL
Intervention: GOALS training
Number of subjects: 40
Study 33019861 — intervention group
Group type: COMPARATOR
Intervention: Brain-Health Education (BHE) training
Number of subjects: 40
Study 32384703 — intervention group
Group type: EXPERIMENTAL
Intervention: Yield-mapping system using RGB-D stereovision camera and GNSS receiver
Number of subjects: 40
Study 32384703 — intervention group
Group type: EXPERIMENTAL
Intervention: Diameter estimation function
Number of subjects: 40
Study 36189471 — intervention group
Group type: EXPERIMENTAL
Intervention: Double Bundle ACL reconstruction
Number of subjects: 59
Study 36189471 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bundle ACL reconstruction
Number of subjects: 59
Study 36189471 — intervention group
Group type: EXPERIMENTAL
Intervention: Single Bundle with Lateral Plasty ACL reconstruction
Number of subjects: 59
Study 36189471 — intervention group
Group type: COMPARATOR
Intervention: Patients with irreparable medial meniscal tear
Number of subjects: 59
Study 36189471 — intervention group
Group type: COMPARATOR
Intervention: Patients who underwent lateral meniscectomy
Number of subjects: 59
Study 36189471 — intervention group
Group type: COMPARATOR
Intervention: Patients with reparable meniscal tear
Number of subjects: 59
Study 33368499 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg/day
Number of subjects: 60
Study 33368499 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg/day
Number of subjects: 60
Study 33368499 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 15 mg/day
Number of subjects: 60
Study 33368499 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg/day
Number of subjects: 60
Study 33368499 — intervention group
Group type: EXPERIMENTAL
Intervention: Rabeprazole 20 mg/day
Number of subjects: 60
Study 33991999 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA140 (140mg/kg)
Number of subjects: 6
Study 33991999 — intervention group
Group type: COMPARATOR
Intervention: VPA30 (30mg/kg)
Number of subjects: 6
Study 33991999 — intervention group
Group type: EXPERIMENTAL
Intervention: VPA140 (140mg/kg) in injured patient
Number of subjects: 6
Study 35050817 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral extra-articular tenodesis (LET)
Number of subjects: 568
Study 35050817 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased graft diameter
Number of subjects: 568
Study 35050817 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age
Number of subjects: 568
Study 35050817 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater posterior tibial slope
Number of subjects: 568
Study 35050817 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative high-grade knee laxity
Number of subjects: 568
Study 35050817 — intervention group
Group type: EXPERIMENTAL
Intervention: Earlier return to sport
Number of subjects: 568
Study 34129719 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable fillers in male cheeks (inferiomedial placement)
Number of subjects: 200
Study 34129719 — intervention group
Group type: EXPERIMENTAL
Intervention: Injectable fillers in female cheeks (superolateral placement)
Number of subjects: 200
Study 32564804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed fecal immunochemical test outreach plus reminder calls (n=61)
Number of subjects: 782
Study 32564804 — intervention group
Group type: EXPERIMENTAL
Intervention: Mailed invitation to screen and reminder phone calls (n=261)
Number of subjects: 782
Study 32564804 — intervention group
Group type: COMPARATOR
Intervention: Usual opportunistic screening during a healthcare visit (n=260)
Number of subjects: 782
Study 34853915 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% articaine single buccal infiltration
Number of subjects: 30
Study 34853915 — intervention group
Group type: COMPARATOR
Intervention: 2% lidocaine routine buccal and palatal injections
Number of subjects: 30
Study 32006028 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutrient supplementation (LNS) for children aged 6-18 months (T2)
Number of subjects: 3561
Study 32006028 — intervention group
Group type: COMPARATOR
Intervention: Lipid-based nutrient supplementation (LNS) for pregnant/lactating women (T3)
Number of subjects: 3561
Study 32006028 — intervention group
Group type: COMPARATOR
Intervention: Control group (T0)
Number of subjects: 3561
Study 32006028 — intervention group
Group type: COMPARATOR
Intervention: Parenting messages (T4)
Number of subjects: 3561
Study 36192565 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclofenac controlled-release (CR) 200 mg once-a-day for 4 weeks
Number of subjects: 14543
Study 33656561 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention with incentives for submitting a urine sample indicating alcohol abstinence for 12 weeks.
Number of subjects: 158
Study 33656561 — intervention group
Group type: COMPARATOR
Intervention: Control group with incentives for submitting a urine sample without the requirement of alcohol abstinence for 12 weeks.
Number of subjects: 158
Study 33656561 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency management intervention
Number of subjects: 158
Study 32792449 — intervention group
Group type: EXPERIMENTAL
Intervention: Musculoskeletal physiotherapy combined with occlusal splint and education
Number of subjects: 0
Study 32792449 — intervention group
Group type: COMPARATOR
Intervention: Occlusal splint and education alone
Number of subjects: 0
Study 35961278 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 µg/wk of vitamin B12 supplementation for 90 days
Number of subjects: 0
Study 35961278 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels of holotranscobalamin
Number of subjects: 0
Study 35961278 — intervention group
Group type: COMPARATOR
Intervention: Baseline levels of homocysteine
Number of subjects: 0
Study 35961278 — intervention group
Group type: COMPARATOR
Intervention: Comparison of VE-cadherin levels between VEG women and VEG men
Number of subjects: 0
Study 34952856 — intervention group
Group type: EXPERIMENTAL
Intervention: Cash or food transfers (US$11/month) for 6 months contingent on timely attendance
Number of subjects: 800
Study 34952856 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 800
Study 32777376 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral-sutured enVista MX60 IOLs with postoperative fractures
Number of subjects: 23
Study 32777376 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral-sutured enVista MX60 IOLs with intraoperative fractures
Number of subjects: 23
Study 32777376 — intervention group
Group type: COMPARATOR
Intervention: Postoperative fractures
Number of subjects: 23
Study 32777376 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture materials used
Number of subjects: 23
Study 32777376 — intervention group
Group type: EXPERIMENTAL
Intervention: Time until postoperative fracture
Number of subjects: 23
Study 32777376 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat displacements
Number of subjects: 23
Study 35774519 — intervention group
Group type: EXPERIMENTAL
Intervention: Yupingfeng (YPF) granules
Number of subjects: 351
Study 35774519 — intervention group
Group type: COMPARATOR
Intervention: pidotimod
Number of subjects: 351
Study 35774519 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 351
Study 33025051 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (3 mg/kg)
Number of subjects: 12
Study 36349887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alteplase
Number of subjects: 1362
Study 33676007 — intervention group
Group type: EXPERIMENTAL
Intervention: Full ERAS program
Number of subjects: 144
Study 33676007 — intervention group
Group type: COMPARATOR
Intervention: Limited ERAS management
Number of subjects: 144
Study 32424486 — intervention group
Group type: COMPARATOR
Intervention: Continuous basal infusion of 0.15% levobupivacaine at 3 ml/h (group C)
Number of subjects: 50
Study 32424486 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed intermittent boluses of local anesthetic (12 ml every 4 h) (group PIB)
Number of subjects: 50
Study 32424486 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (C and PIB)
Number of subjects: 50
Study 35118795 — intervention group
Group type: EXPERIMENTAL
Intervention: mi. spot (online intervention)
Number of subjects: 41
Study 35118795 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 41
Study 32435967 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention to increase dietary intake during chemotherapy
Number of subjects: 155
Study 32435967 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low protein intake (< 0.8 g kg-1 day-1) before chemotherapy
Number of subjects: 155
Study 32435967 — intervention group
Group type: EXPERIMENTAL
Intervention: 5.0-9.9% weight loss before chemotherapy
Number of subjects: 155
Study 36858059 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT) with a reduced dose of 60 Gy and concurrent weekly cisplatin in N+ patients
Number of subjects: 61
Study 36858059 — intervention group
Group type: COMPARATOR
Intervention: Trans-oral surgery (TOS) and neck dissection (ND) with adjuvant reduced-dose RT depending on pathologic findings
Number of subjects: 61
Study 34452610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided single popliteal sciatic nerve block
Number of subjects: 120
Study 34452610 — intervention group
Group type: COMPARATOR
Intervention: Control group (no ultrasound-guided single popliteal sciatic nerve block)
Number of subjects: 120
Study 36151017 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin
Number of subjects: 118
Study 36151017 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel
Number of subjects: 118
Study 32142578 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided Bone Regeneration (GBR) procedure
Number of subjects: 45
Study 32142578 — intervention group
Group type: COMPARATOR
Intervention: Control (implants placed in native bone)
Number of subjects: 45
Study 32142578 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (GBR and control)
Number of subjects: 45
Study 33966345 — intervention group
Group type: EXPERIMENTAL
Intervention: F-MRP supplementation for 8 weeks
Number of subjects: 50
Study 33966345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 32938468 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity-modulated radiation therapy (IMRT)
Number of subjects: 60
Study 32938468 — intervention group
Group type: COMPARATOR
Intervention: Three-dimensional conformal radiotherapy (3D-CRT)
Number of subjects: 60
Study 34309223 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized CARTs-defined CAN
Number of subjects: 311
Study 34309223 — intervention group
Group type: EXPERIMENTAL
Intervention: SDNN
Number of subjects: 311
Study 34309223 — intervention group
Group type: EXPERIMENTAL
Intervention: rMSSD
Number of subjects: 311
Study 34309223 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SDNN and rMSSD
Number of subjects: 311
Study 33472241 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact-umbilical cord milking (I-UCM)
Number of subjects: 587
Study 33472241 — intervention group
Group type: COMPARATOR
Intervention: Cut-umbilical cord milking (C-UCM)
Number of subjects: 587
Study 33472241 — intervention group
Group type: COMPARATOR
Intervention: Immediate cord clamping (ICC)
Number of subjects: 587
Study 35931908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm (physicians completed a 2-h online course in SDM communication skills and received electronic reminders)
Number of subjects: 466
Study 35931908 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm
Number of subjects: 466
Study 35931908 — intervention group
Group type: COMPARATOR
Intervention: Comparator arm (received reminders only)
Number of subjects: 466
Study 32978014 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with external beam radiotherapy (EBRT) to the prostate
Number of subjects: 432
Study 32978014 — intervention group
Group type: COMPARATOR
Intervention: Androgen deprivation therapy (ADT) alone
Number of subjects: 432
Study 35226531 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg of dexamethasone
Number of subjects: 0
Study 35226531 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of dexamethasone
Number of subjects: 0
Study 33720065 — intervention group
Group type: COMPARATOR
Intervention: PEEP 3 cmH2O
Number of subjects: 0
Study 33720065 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 6 cmH2O
Number of subjects: 0
Study 33720065 — intervention group
Group type: EXPERIMENTAL
Intervention: PEEP 9 cmH2O
Number of subjects: 0
Study 32819864 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesiotherapy treatment protocol (KTP)
Number of subjects: 57
Study 32819864 — intervention group
Group type: COMPARATOR
Intervention: Amitriptyline alone (control)
Number of subjects: 57
Study 33988708 — intervention group
Group type: EXPERIMENTAL
Intervention: Flotation-REST intervention (5 sessions, 60-90 minutes each, separated by 4 days)
Number of subjects: 99
Study 33988708 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment (5 sessions, 60-90 minutes each, separated by 4 days)
Number of subjects: 99
Study 33988708 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (no additional treatment)
Number of subjects: 99
Study 32862667 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine (0.5 mg twice daily for the first month, then 0.5 mg daily for 11 months)
Number of subjects: 795
Study 32862667 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 795
Study 32862667 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 795
Study 35112520 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole
Number of subjects: 44
Study 35112520 — intervention group
Group type: COMPARATOR
Intervention: Ropinirole
Number of subjects: 44
Study 32959590 — intervention group
Group type: EXPERIMENTAL
Intervention: Fire needling bloodletting, applied twice a week for 4 weeks
Number of subjects: 60
Study 32959590 — intervention group
Group type: COMPARATOR
Intervention: Operation
Number of subjects: 60
Study 35235856 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial pain management intervention
Number of subjects: 0
Study 33063576 — intervention group
Group type: EXPERIMENTAL
Intervention: Child Posture Variability Coding (CPVC)
Number of subjects: 10
Study 32701843 — intervention group
Group type: EXPERIMENTAL
Intervention: MBSR+
Number of subjects: 98
Study 32701843 — intervention group
Group type: COMPARATOR
Intervention: SMH
Number of subjects: 98
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Very early mobilisation after stroke
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: No previous diabetes
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower stroke severity
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Less 3-month depressive traits (IDA scale)
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Less 3-month disability (modified Rankin Scale)
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior full-time work
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Younger age (multivariable analysis)
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower stroke severity (multivariable analysis)
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior full-time work (multivariable analysis)
Number of subjects: 376
Study 34325037 — intervention group
Group type: EXPERIMENTAL
Intervention: Less 3-month disability (multivariable analysis)
Number of subjects: 376
Study 32921545 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative management without drainage tube placement
Number of subjects: 42
Study 32921545 — intervention group
Group type: COMPARATOR
Intervention: Post-operative management with drainage tube placement
Number of subjects: 42
Study 35670414 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone (1 g) and metronidazole (500 mg) 30–60 min before incision
Number of subjects: 162
Study 35670414 — intervention group
Group type: COMPARATOR
Intervention: Multiple-dose ceftriaxone and metronidazole followed by cefuroxime and metronidazole for 5 days
Number of subjects: 162
Study 35670414 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose ceftriaxone and metronidazole
Number of subjects: 162
Study 33168657 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib plus Fulvestrant
Number of subjects: 0
Study 33168657 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Fulvestrant
Number of subjects: 0
Study 34015478 — intervention group
Group type: EXPERIMENTAL
Intervention: Finerenone
Number of subjects: 5674
Study 34015478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5674
Study 32519782 — intervention group
Group type: EXPERIMENTAL
Intervention: DAA group (509 patients who achieved sustained virological response after DAA therapy)
Number of subjects: 719
Study 32519782 — intervention group
Group type: COMPARATOR
Intervention: Non‐DAA group (210 patients who did not receive DAAs)
Number of subjects: 719
Study 34744156 — intervention group
Group type: EXPERIMENTAL
Intervention: Etco2 levels 40 mm Hg or higher (group H)
Number of subjects: 90
Study 33429127 — intervention group
Group type: EXPERIMENTAL
Intervention: Terazosin quantification using LC-MS/MS method
Number of subjects: 935
Study 32662862 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation (1.2 g/d from randomization to 36 weeks' postmenstrual age)
Number of subjects: 528
Study 32662862 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 528
Study 32662862 — intervention group
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Number of subjects: 528
Study 35024838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin (4 g every 6 hours)
Number of subjects: 161
Study 35024838 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone or meropenem (if resistant)
Number of subjects: 161
Study 33835939 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 274
Study 33835939 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg SNF472
Number of subjects: 274
Study 33835939 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg SNF472
Number of subjects: 274